Evaluation of Safety and Tolerability of Libella Gene Therapy for Critical Limb Ischemia: AAV- hTERT
Status:
Unknown status
Trial end date:
2020-12-01
Target enrollment:
Participant gender:
Summary
Using gene therapy to express active telomerase (hTERT) in human cells has the potential to
treat many diseases related to aging, including critical limb ischemia (CLI).
This study will entail treating subjects with hTERT delivered via transduction using AAV. The
goal is to extend the telomeres to prevent, delay, or even reverse the development of the
pathology of CLI. It is expected to have a direct consequence on function and quality of life
in patients with Peripheral artery disease (PAD); in this case a subgroup of patients with
CLI, the worst presentation of PAD.